Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... program,” said Danny Bar-Zohar, global head

Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

Under the terms of the agreement, Merck KGaA will pay Artios $30m upfront, as well as near-term payments. ... Artios could also receive royalty payments up to double digits on net sales of each product commercialised by Merck KGaA.

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux. French pharma group Pierre Fabre’s Braftovi has been recommended for NHS use by the UK’s National Institute for Health ... Braftovi (encorafenib) combined with has been recommended Merck

Switzerland: a life sciences hub

When Merck acquired Serono, the company also acquired several manufacturing facilities in the canton of Vaud. ... The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline,

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]